Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
Date:1/29/2009

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufac
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... New York, NY (PRWEB) November 20, 2014 ... ) is now available as an open access journal ... cells with infrared fluorescent proteins to preserve photoresponsiveness in ... Two-color fluorescent in situ hybridization using chromogenic ... microfluidics chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3
... Nov. 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... Capital Markets Focus on Healthcare Conference on,Wednesday, December 5, ... Hotel in New York City., To access the ... to,Nastech,s website at http://www.nastech.com approximately 15 minutes ...
... FDA 510(k) (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening ... ... Colo., Nov. 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ... for animals and humans, has,received an official response from the Food ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,300,650 entitled "Reovirus for the Treatment of Neoplasia.",The ... treat cancers that,have inactivated PKR, whether the PKR ... factors. PKR is a host cellular protein responsible ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers ... a second chancejust not as they originally thought. ... harnessed from bone marrow that were believed to have ... if injected into the heart within two weeks of ...
... step closer to understanding what drives tumor metastasis, as ... can slow their own growth. In a recent ... the American Association for Cancer Research, Ral A. Ruggiero, ... medicine at the National Academy of Medicine in Buenos ...
... Findings from preclinical studies in a skin ... alone, or first-generation BRAF inhibitors used in combination ... have the potential to prevent drug-induced skin lesions ... The studies, presented at the AACR-NCI-EORTC International ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
Biology Products: